Peptides DB
Research-centric peptide and protocol reference hub
Study 31 of 31Pasireotide literatureArchives of endocrinology and metabolism · Meta-analysisHigh-impact journal2026

Effectiveness and safety of pharmacological treatments for Cushing's disease: An updated systematic review and meta-analysis.

Pasireotide has a disease control rate of 42% in Cushing's disease, but clinicians should be cautious due to the very low certainty of evidence and the risk of dysglycemia.

Read at Archives of endocrinology and metabolismAdd to compare

Where it sits

this study against the rest of the pasireotide corpus
1
Preclinical
20
Observational
0
Open-label
3
Randomised
7
Reviews · this one

Summary and findings

This systematic review assessed the efficacy and safety of pharmacological treatments for Cushing's disease, including pasireotide, in a population of 580 patients across 10 studies. The disease control rate for pasireotide was reported as 42%. The study also highlighted adverse events associated with the treatments, particularly dysglycemia linked to pasireotide.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Disease control rate for pasireotide was 42% (95% CI: 28-58%; 10 studies, 580 patients).n=5802026

Abstract

The authors’ words, as Archives of endocrinology and metabolism supplied them

<h4>Objective</h4>To provide an updated assessment of the efficacy, safety, and clinical outcomes of pharmacological treatments for Cushing's disease, focusing on cabergoline, ketoconazole, pasireotide, and osilodrostat.<h4>Materials and methods</h4>This systematic review update was conducted using the Joanna Briggs Institute methodology. Outcomes included disease control rates, adverse events, and improvements in comorbidities and quality of life.<h4>Results</h4>Eleven new studies were included. In the updated analysis, disease control rates were 35.5% for cabergoline (95% confidence interval [CI]: 28-43%; 7 studies, 155 patients), 42% for ketoconazole (95% CI: 38-47%; 7 studies, 488 patients), 42% for pasireotide (95% CI: 28-58%; 10 studies, 580 patients), and 67% for osilodrostat (95% CI: 61-73%; 4 studies, 263 participants). According to GRADE, certainty of evidence was very low for pasireotide and low for the other agents. Osilodrostat increased cortisol normalization 4.56-fold versus placebo (95% CI: 1.53-13.56; 2 studies, 144 patients; moderate certainty). Osilodrostat and pasireotide improved CushingQoL scores by 13.23 points (95% CI: 10.78-15.68) and 8.96 points (95% CI: 4.37-13.55), respectively. Pasireotide was predominantly associated with dysglycemia. Cabergoline most often caused mild adverse events, with treatment escape in 11%. Ketoconazole was linked to mildly elevated transaminases and gastrointestinal symptoms. Osilodrostat most commonly resulted in fatigue and adrenal insufficiency, often reflecting therapeutic response.<h4>Conclusion</h4>Pharmacological disease control rates in Cushing's disease range from 35.5% to 67%, with osilodrostat achieving the highest rates and being the only agent supported by placebo-controlled evidence demonstrating a statistically significant effect. In the absence of head-to-head comparisons, treatment decisions remain individualized.

Background

This paper addresses the effectiveness and safety of pharmacological treatments for Cushing's disease, a condition characterized by excess cortisol. Prior studies have indicated varying efficacy among treatments, but this review aims to provide a comprehensive update on recent findings. Understanding the comparative effectiveness of these agents is crucial for guiding clinical decisions.

Methods

The study utilized the Joanna Briggs Institute methodology for systematic review. It included 11 new studies focusing on disease control rates, adverse events, and improvements in comorbidities and quality of life. The population included patients with Cushing's disease treated with various pharmacological agents.

Results

The primary endpoint for pasireotide showed a disease control rate of 42% (95% CI: 28-58%; 10 studies, 580 patients). Osilodrostat demonstrated a higher disease control rate of 67% (95% CI: 61-73%; 4 studies, 263 participants). Improvements in CushingQoL scores were reported as 8.96 points for pasireotide (95% CI: 4.37-13.55).

Interpretation

While pasireotide demonstrated a disease control rate of 42%, the evidence quality was rated very low, indicating uncertainty in its effectiveness. Compared to osilodrostat, which had a higher disease control rate and moderate certainty evidence, the clinical significance of pasireotide's effect may be limited. The findings suggest that treatment choices should be individualized, taking into account the varying levels of evidence and potential adverse effects.

Key findings

  • Disease control rate of 42% for pasireotide (95% CI: 28-58%; 10 studies, 580 patients)
  • Osilodrostat achieved a disease control rate of 67% (95% CI: 61-73%; 4 studies, 263 participants)
  • CushingQoL scores improved by 8.96 points for pasireotide (95% CI: 4.37-13.55)
  • Osilodrostat increased cortisol normalization 4.56-fold versus placebo (95% CI: 1.53-13.56; 2 studies, 144 patients)
  • Certainty of evidence for pasireotide was rated as very low according to GRADE

Limitations

  • Certainty of evidence for pasireotide rated as very low
  • No head-to-head comparisons available
  • Adverse events predominantly included dysglycemia
  • Study included multiple pharmacological agents without direct comparisons

Elsewhere in the Pasireotide corpus

AImpact of perioperative corticosteroids on postoperative morbidity after pancreaticoduodenectomy: A systematic review, meta-analysis, and trial sequential analysis.Surgery · 2026 · n=454 · Clinically relevant postoperative pancreatic fistula was significantly reduced with corticosteroids (primary analysis: risk difference, -0.09; 95% confidence interval, -0.17 to -0.01; number needed to treat, 11).reviewBRecurrent Cushing's disease due to postoperative seeding of tumor cells in the sphenoid sinus: a case report with review of the literature.Endocrine journal · 2026 · n=1 · Not reported in abstract.HumanBPasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas.Pituitary · 2026 · n=6 · Median follow-up of 3.3 years (range 0.5 to 5.9).HumanBPredictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.Journal of neuroendocrinology · 2023 · n=44 · No significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).In vitroCPredictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors.Journal of neuroendocrinology · 2026 · No significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).In vitroBApproach to the patient: precision medicine-guided evaluation and treatment of acromegaly.The Journal of clinical endocrinology and metabolism · 2026 · 80% of patients achieved hormonal control with biomarker-guided treatment.review